EBioMedicine (Sep 2019)

Intradermal vaccination prevents anti-MOG autoimmune encephalomyelitis in macaquesResearch in context

  • Claire-Maëlle Fovet,
  • Lev Stimmer,
  • Vanessa Contreras,
  • Philippe Horellou,
  • Audrey Hubert,
  • Nabila Seddiki,
  • Catherine Chapon,
  • Sabine Tricot,
  • Carole Leroy,
  • Julien Flament,
  • Julie Massonneau,
  • Nicolas Tchitchek,
  • Bert A. 't Hart,
  • Sandra Zurawski,
  • Peter Klucar,
  • Philippe Hantraye,
  • Kumaran Deiva,
  • Gerard Zurawski,
  • SangKon Oh,
  • Roger Le Grand,
  • Ché Serguera

Journal volume & issue
Vol. 47
pp. 492 – 505

Abstract

Read online

Background: Autoimmune demyelinating diseases (ADD) are a major cause of neurological disability due to autoreactive cellular and humoral immune responses against brain antigens. A cure for chronic ADD could be obtained by appropriate immunomodulation. Methods: We implemented a preclinical scheme to foster immune tolerance to myelin oligodendrocyte glycoprotein (MOG), in a cynomolgus-macaque model of experimental autoimmune encephalomyelitis (EAE), in which administration of recombinant human MOG (rhMOG) elicits brain inflammation mediated by MOG-autoreactive CD4+ lymphocytes and anti-MOG IgG. For immunotherapy, we used a recombinant antibody (Ab) directed against the dendritic cell-asialoglycoprotein receptor (DC-ASGPR) fused either to MOG or a control antigen PSA (prostate-specific antigen). Findings: rhMOG and the anti-DC-ASGPR-MOG were respectively detected in CD1a+ DCs or CD163+ cells in the skin of macaques. Intradermal administration of anti-DC-ASGPR-MOG, but not control anti-DC-ASGPR-PSA, was protective against EAE. The treatment prevented the CD4+ T cell activation and proinflammatory cytokine production observed in controls. Moreover, the administration of anti-DC-ASGPR-MOG induced MOG-specific CD4+CD25+FOXP3+CD39+ regulatory lymphocytes and favoured an upsurge in systemic TGFβ and IL-8 upon rhMOG re-administration in vivo. Interpretation: We show that the delivery of an anti-DC-ASGPR-MOG allows antigen-specific adaptive immune modulation to prevent the breach of immune tolerance to MOG. Our findings pave the way for therapeutic vaccines for long-lasting remission to grave encephalomyelitis with identified autoantigens, such as ADD associated with anti-MOG autoantibodies. Fund: Work supported by the French ANR (ANR-11-INBS-0008 and ANR-10-EQPX-02-01), NIH (NIH 1 R01 AI 105066), the Baylor Scott and White Healthcare System funding and Roche Research Collaborative grants. Keywords: EAE, TGFβ, Tolerance, Treg, Anti-MOG IgG, Macaque